The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Gilead Sciences (I)
Research Funding - Juno Therapeutics
Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors.
 
Cameron Chalker
No Relationships to Disclose
 
Vicky Wu
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Victoria Hwang
No Relationships to Disclose
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi; NCCN; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Jay Justin Liao
No Relationships to Disclose
 
Sylvia Lee
Patents, Royalties, Other Intellectual Property - Patent for BRAF-specific TCR, licensed to Lyell Immunopharma.
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Neal D. Futran
No Relationships to Disclose
 
Jeffrey Houlton
No Relationships to Disclose
 
Brittany Barber
No Relationships to Disclose
 
Upendra Parvathaneni
No Relationships to Disclose
 
George E. Laramore
No Relationships to Disclose
 
Rafael Santana-Davila
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Cullinan Oncology; Genentech/Roche; Lilly; NGM Biopharmaceuticals; Takeda Science Foundation
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst)
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst)
 
Renato G. Martins
Honoraria - Roche/Genentech
Research Funding - Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Cristina P. Rodriguez
Consulting or Advisory Role - AstraZeneca (I); Merck (I)
Speakers' Bureau - CUE Biopharma
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Ignyta (Inst); Kura Oncology (Inst); Merck (Inst)